12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Deals

Jennerex, Transgene deal

Jennerex granted Transgene exclusive rights to develop and commercialize JX-594 in Europe, the Commonwealth of Independent States and the Middle East. The partners will co-develop the recombinant vaccinia virus (TK-deletion plus...

Read the full 143 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >